Pulmonx is a commercial-stage lung-device company whose equity debate is no longer about whether the Zephyr endobronchial valve works. The debate is whether a still-narrow treating-physician funnel can convert enough severe-emphysema patients into procedures to outrun cash burn before the balance sheet forces a dilutive raise. That conversion problem, not the clinical claim, is what the current multiple is actually pricing.
The most important recent development is the mid-year commercial print, in which worldwide procedure volume kept growing while the United States account base remained the binding constraint. Management continues to treat new treating-center activation and Chartis-guided patient selection as the operating levers, because a valve cannot be sold into a hospital that has not trained an interventional pulmonologist and built a workup pathway. The mechanism is slow on purpose: each new account has to learn collateral-ventilation screening, schedule the workup, and then produce a first cluster of treated patients before the center becomes a recurring buyer. Shareholders feel that lag as a gap between a large diagnosed-emphysema pool and a still-small treated-patient count.
The tension is that gross margin on the valve is already high enough to look like a scaled device franchise, while operating expense still behaves like a company buying awareness one hospital at a time. Cash on the balance sheet is finite, and the company has already used at-the-market equity capacity when the share price allowed it. If treating-account productivity stalls, the equity is left funding a salesforce that cannot harvest the installed base fast enough. The strongest counterargument is that reimbursement is already in place in the major markets and that the clinical literature is no longer the gating item, so the remaining work is commercial execution rather than a binary regulatory event.
What resolves the case over the next several reporting periods is treating-account productivity, not another efficacy paper. Watch worldwide Zephyr procedure growth against cash used in operations and against the pace of new treating-center adds. If procedures keep compounding while the cash draw shrinks, the conversion thesis is working. If accounts stay open but procedures flatten, the franchise is a high-margin product trapped in a low-throughput sales motion.